Market news

Orthofix Medical recently saw its analyst price target move from US$15 to US$13, a reset that anchors the latest round of valuation work on the stock. Analysts link this change to updated views on revenue, cash generation and the impact of the MDR transition, even as many maintain a constructive long-term stance. Read on to see what is driving the shift in targets and how you can track the evolving Orthofix Medical story from here. Analyst Price Targets don't always capture the full story...

Orthofix Medical (NASDAQ:OFIX) executives said the company’s updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among s

Detailed price information for Viatris Inc (VTRS-Q) from The Globe and Mail including charting and trades.

Orthofix Medical Inc (OFIX) delivers 5% pro forma growth, raises EBITDA guidance, and navigates a complex landscape of European MDR opportunities and U.S. distributor headwinds.

Moby summary of Orthofix Medical Inc.'s Q2 2026 earnings call

Motley Fool Press Release.

Orthofix (OFIX) delivered earnings and revenue surprises of +333.33% and +0.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Orthofix Medical (NASDAQ:OFIX) reported second-quarter results that management said reflected improving operating trends across several businesses, while continued weakness among smaller U.S. spine distributors remained a headwind. The company reiterated its focus on commercial productivity, discipl

LEWISVILLE, Texas, August 05, 2026--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, reflecting progress toward a more focused and consistent operating model. The Company also raised its full-year 2026 guidance for both net sales and adjusted EBITDA. All pro forma measures contained within this release exclude the impact of the discontinued M6™ product lines.

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rewey Asset Management, an investment management firm, released its “RAM Smid Composite” investor letter for the second quarter of 2026. A copy of the letter can be downloaded here. Rewey Asset Management, an investment management firm, released its “RAM Smid Composite” investor letter for the second quarter of 2026. RAM Smid Composite gained 20.06% in the […]

The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Orthofix (OFIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

LEWISVILLE, Texas, July 20, 2026--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferences:

LEWISVILLE, Texas, July 15, 2026--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day.

Detailed price information for Orthofix Intl NV (OFIX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Orthofix Intl NV (OFIX-Q) from The Globe and Mail including charting and trades.